Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries. Many of these discoveries are powerful examples of how carefully designed basic research can lead to new approaches that block or interact with key pathways in diseased cells, resulting in better treatments with durable effects and lower toxicity.
European hematologists have pioneered important inventions and played leading roles in developing curative approaches for patients with hematologic diseases, such as lymphomas and leukemias.
EHA aims to foster science and spread knowledge in basic, translational, and clinical research in hematology in Europe. The updated EHA Research Roadmap identifies priorities and needs across the different areas of hematology, including normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, hematopoietic stem cell transplantation, CAR-T and other cell-based immune therapies, and gene therapy.
A fundamental component of EHA initiatives for research in hematology are EHA Scientific Working Groups. Read about the structure of the 24 SWGs, how to apply, or how to participate in Scientific Meetings.
To accelerate the careers of promising scientists, EHA provides opportunities in:
EHA also honors the contribution of outstanding physicians and scientists for the advancement of hematology through the: